Innovent Biologics Inc. (IVBXF.OB) announced that Phase 3 clinical trial results have shown that mazdutide significantly outperforms dulaglutide in managing glycemic control and reducing body weight among Chinese participants with type 2 diabetes. Furthermore, mazdutide was found to enhance several cardiometabolic risk factors, including blood pressure, lipids, serum uric acid, and liver enzymes.Mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, has demonstrated significant efficacy in Chinese adults with type 2 diabetes (T2D) in the DREAMS-2 study. These findings were unveiled during a late-breaking oral presentation at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD).Additionally, initial Phase 3 results from the GLORY-1 study, focusing on weight loss in overweight/obese subjects, were presented in an oral session at EASD. Mazdutide promises to be a breakthrough weight-loss drug, offering dual-targeted fat burning, liver function improvement, and durable weight reduction, delivering comprehensive metabolic advantages that support weight loss and promote a healthier lifestyle.The DREAMS-2 trial included 731 Chinese participants with type 2 diabetes (mean age 51.8 years, mean baseline HbA1c 8.22%, mean baseline body weight 76.95 kg), who had inadequate control with metformin alone or in combination with other oral anti-diabetic medications. The participants were randomized to receive either mazdutide 4 mg, mazdutide 6 mg, or dulaglutide 1.5 mg for 28 weeks, with the primary endpoint being the change in HbA1c from baseline to week 28.According to Innovent, after 28 weeks, the mean reductions in HbA1c from baseline were 1.69% for mazdutide 4 mg and 1.73% for mazdutide 6 mg, both showing superiority over dulaglutide 1.5 mg, which showed a 1.36% reduction.Moreover, participants treated with mazdutide experienced significant weight reduction, with mean weight losses of 9.24% for the 4 mg dose and 7.13% for the 6 mg dose, compared to a 2.86% reduction with dulaglutide.The material has been provided by InstaForex Company – www.instaforex.com
- Philippines’ FX Reserves Climb to $112 Billion in September - October 7, 2024
- Czech Republic’s Trade Balance Swings to Surplus in August 2024 - October 7, 2024
- Czech Republic’s Industrial Production Rebounds with 1.5% Growth in August 2024 - October 7, 2024
